Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Prospective, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer.

NCT03433560 is registered in ClinicalTrials.gov with Kyowa Kirin Korea Co., Ltd. as lead sponsor.

NCT NCT03433560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03433560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Prospective, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer.
Lead sponsor
Kyowa Kirin Korea Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
January 18, 2018
Completion date
June 30, 2021
Enrollment
1,300 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, breast neoplasm female